Market Overview

Kedalion Therapeutics Closes $5 Million Series A Financing Round


Kedalion Therapeutics, Inc., a clinical-stage company focused on the
development and commercialization of topical ophthalmology therapies
based on its proprietary AcuStream™ platform, today announced the
completion of a $5 million Series A financing. The investment round was
led by Lagunita Biosciences. Proceeds from the financing will be used to
further develop the Company's technology platform through to pilot-scale
GMP manufacturing and support advancement of the Company's clinical

"We are very pleased to secure this round of financing, which will
enable us to advance the AcuStream technology and to generate additional
clinical data to further show our platform's broad benefits for
ophthalmology patients. We are also extremely pleased to have the
continued support of Lagunita Biosciences as we develop our innovative
products," said Peter Noymer, PhD, President and Chief Executive
Officer, Kedalion Therapeutics.

"Kedalion's AcuStream platform has the potential to revolutionize the
way that ophthalmology patients take their medications and to have great
impact on comfort, convenience, compliance and adherence with their
therapies," said Mark Blumenkranz, MD, MMS, Executive Chairman of
Kedalion and Chairman of Lagunita Biosciences. "The novelty and
transformative potential of Kedalion's AcuStream platform represents the
kind of innovation that we are trying to foster at Lagunita, and we are
pleased to support Kedalion's growth."

About Kedalion Therapeutics

Kedalion Therapeutics is a venture-backed, clinical-stage biotechnology
company whose mission is to bring to market transformative topical
ophthalmic therapies for new and existing indications. Kedalion's
proprietary AcuStream platform technology delivers topical drugs to the
eye in a precise and accurate manner that enables comparable effect with
up to an 80% reduction in dose compared to standard eye drops. Kedalion
is based in Menlo Park, CA. For more information, visit

View Comments and Join the Discussion!